Puma Biotechnology Inc (PBYI) Earns Outperform Rating from Leerink Swann

Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “outperform” rating restated by Leerink Swann in a research note issued to investors on Monday, Marketbeat reports. They currently have a $115.00 price target on the biopharmaceutical company’s stock. Leerink Swann’s target price would suggest a potential upside of 33.95% from the stock’s previous close.

A number of other brokerages have also issued reports on PBYI. Credit Suisse Group reiterated an “outperform” rating and set a $58.00 price target on shares of Puma Biotechnology in a research report on Tuesday, April 18th. Stifel Nicolaus reiterated a “buy” rating and set a $88.00 price target on shares of Puma Biotechnology in a research report on Wednesday, April 19th. Royal Bank of Canada set a $40.00 price target on Puma Biotechnology and gave the stock a “hold” rating in a research report on Wednesday, May 10th. Zacks Investment Research upgraded Puma Biotechnology from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Tuesday, May 16th. Finally, Citigroup Inc. reiterated a “buy” rating and set a $88.00 price target on shares of Puma Biotechnology in a research report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Puma Biotechnology has an average rating of “Buy” and an average target price of $89.75.

Puma Biotechnology (NYSE:PBYI) traded down 1.38% during midday trading on Monday, hitting $85.85. The stock had a trading volume of 699,152 shares. The stock has a 50-day moving average price of $70.29 and a 200 day moving average price of $44.73. Puma Biotechnology has a one year low of $28.35 and a one year high of $92.00. The firm’s market cap is $3.17 billion.

Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.06) by $0.09. On average, analysts predict that Puma Biotechnology will post ($8.50) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Puma Biotechnology Inc (PBYI) Earns Outperform Rating from Leerink Swann” was first reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.wkrb13.com/markets/2285013/puma-biotechnologys-nysepbyi-outperform-rating-reiterated-at-leerink-swann.html.

In other Puma Biotechnology news, major shareholder Adage Capital Partners Gp, L.L sold 247,260 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.32, for a total value of $19,859,923.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 1,990,088 shares of company stock worth $157,553,113 over the last three months. 22.70% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Fox Run Management L.L.C. acquired a new position in Puma Biotechnology during the second quarter valued at $227,000. Bank of Montreal Can acquired a new position in Puma Biotechnology during the first quarter valued at $195,000. Alambic Investment Management L.P. acquired a new position in Puma Biotechnology during the first quarter valued at $201,000. Parametric Portfolio Associates LLC acquired a new position in Puma Biotechnology during the first quarter valued at $257,000. Finally, Weiss Multi Strategy Advisers LLC acquired a new position in Puma Biotechnology during the first quarter valued at $335,000. Institutional investors own 80.98% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285013/puma-biotechnologys-nysepbyi-outperform-rating-reiterated-at-leerink-swann.html

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.